6 Related NICE guidance

Published

  • Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance 155 (2008). Available from www.nice.org.uk/guidance/TA155

  • Guidance on the use of photodynamic therapy for age-related macular degeneration. NICE technology appraisal guidance 68 (2003). Available from www.nice.org.uk/guidance/TA68

Under development

NICE is developing the following guidance (details available from www.nice.org.uk):

  • Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion. NICE technology appraisal (publication date to be confirmed).

  • Ranibizumab for the treatment of diabetic macular oedema. NICE technology appraisal (publication date to be confirmed).

  • Pegaptanib sodium for the treatment of diabetic macular oedema. NICE technology appraisal (publication date to be confirmed).

  • National Institute for Health and Care Excellence (NICE)